课题基金 / 基金详情

Small molecule inhibitors for the study of colibactin-induced carcinogenesis by gut microbes

Small molecule inhibitors for the study of colibactin-induced carcinogenesis by gut microbes
用于研究肠道微生物大肠杆菌素诱导癌变的小分子抑制剂
批准号:
10320374
负责人:
Matthew Robert Volpe
金额:
$1.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-02-01 至 2022-06-10
关键词:
AddressAnabolismAnimal ModelAsparagineBacteriaBindingBiological AssayBiologyBiopsyBoronic AcidsCancer EtiologyCell Cycle ArrestCellsCellular AssayCessation of lifeChemicalsChemistryChromosomal InstabilityClinical ResearchCollaborationsColorectal CancerCommunitiesComplexCrystallizationDNADNA AdductionDNA AlkylationDNA CrosslinkingDNA Crosslinking AgentDNA Double Strand BreakDevelopmentEnzymesEpithelial CellsEscherichia coliExposure toFluoridesFluorogenic SubstrateFutureGene ClusterGeneticGenomic IslandsHealthHumanHuman MicrobiomeHydrolysisHydrophobicityIn VitroIncidenceInfectionInstitutesKetonesKnowledgeLengthLinkMammalian CellMolecular TargetMusMutagensMutationNatural ProductsOrganismPathogenicityPathway interactionsPatientsPeptide HydrolasesPeptidesPositioning AttributePreventionProcessProductionProteomeReportingResearchRiskRisk FactorsRoleSerineStructureTestingTherapeuticTherapeutic InterventionTimeTissuesToxinTumor BurdenTumor TissueUnited StatesUniversitiesWorkX-Ray Crystallographyage groupanalogbasecarcinogenesiscarcinogenicitycohortcolorectal cancer preventioncolorectal cancer progressioncolorectal cancer riskcommensal microbescovalent bondcrosslinkdesigneffectiveness testinggastrointestinal epitheliumgenotoxicitygut microbesgut microbiomegut microbiotahigh throughput screeningin vivoinhibitormembermicrobiome researchmicroorganismmolecular targeted therapiesmortalitymouse modelnovelnovel strategiesnovel therapeuticspathogenperiplasmpreventrational designscaffoldsenescencesmall moleculesmall molecule inhibitortissue culturetooltumor

项目摘要

项目成果

Matthew Robert Volpe的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 结直肠癌(CRC)目前是美国癌症死亡的第二大原因 而且,截至2018年,年轻群体的死亡率呈上升趋势。死亡率上升的原因是 还没有得到充分的解释,并突出了迫切需要更好地了解 儿童权利公约“,并制定新的预防和治疗战略。越来越多的证据表明 人类肠道微生物群的成员是结直肠癌发展的潜在驱动因素。尤其是那些能够 产生一种名为Colibactin的小分子基因毒素可能是这一过程中的关键角色。大肠杆菌素是 由含有PKS基因组岛的共生生物和病原生物产生。数不胜数 研究表明,PKS+E.Coli瞬时感染哺乳动物细胞会导致DNA交联, DNA双链断裂、染色体不稳定和衰老。临床研究表明,PKS+ 与健康对照组相比,结直肠癌(~68%)和炎症性肠病(~40%)患者的细菌更为普遍 (21%),肿瘤组织活检组织比邻近健康组织的活检组织更丰富。在动物身上 与小鼠相比,PKS+E.Coli在结直肠癌小鼠模型中的定植导致肿瘤负荷增加 在非结肠素生产国定居。可能是结肠素致癌的最直接证据 潜在的,最近的工作也表明,当小鼠被PKS+大肠杆菌定植时,Colibactin直接 使肠道上皮细胞中的DNA烷基化,形成DNA加合物。总而言之,这些证据 提示接触Colibactin可能会增加结直肠癌的风险,或通过 链球菌素对DNA烷基化和交联的致突变作用。尽管如此,没有可行的治疗策略 已经出现了防止接触Colibactin的方法,但目前还没有工具来研究这一途径在 一个复杂、健康的肠道微生物群落的背景。这项提议旨在解决这些知识差距。 通过开发有效和特异的结肠素生物合成小分子抑制剂。这种工具化合物 将使我们能够更详细地研究Colibactin如何促进CRC进展,并使我们能够测试 假设使用小分子阻断PKS+细菌产生结肠肌动蛋白可以降低发病风险 为主机开发CRC。这项研究将探索一种新的治疗分子靶点 干预CRC的发展,并为更广泛的科学界提供工具,使 更精确地研究来自共生微生物的小分子毒素对人类健康的影响。
英文摘要
PROJECT SUMMARY/ABSTRACT Colorectal cancer (CRC) is currently the second leading cause of cancer deaths in the United States and, as of 2018, shows an increasing mortality rate in younger age groups. The reason for this rise in mortality has not been fully explained and highlights the urgent need to better understand the causes and risk factors for CRC and develop novel strategies for its prevention and treatment. A growing body of evidence has implicated members of the human gut microbiome as potential drivers of CRC development. In particular, bacteria that produce a small molecule genotoxin known as colibactin may be key players in this process. Colibactin is produced by both commensal and pathogenic organisms which harbor the pks genomic island. Numerous studies have shown that transient infection of mammalian cells with pks+ E. coli leads to DNA crosslinking, DNA double-strand breaks, chromosomal instability, and senescence. Clinical studies have shown that pks+ bacteria are more prevalent in patients with CRC (~68%) and IBD (~40%) in comparison to healthy controls (21%) and are more abundant in tumor tissue biopsies than those from adjacent healthy tissue. In animal models, colonization with pks+ E. coli in a mouse model of CRC leads to increased tumor load relative to mice colonized with non-colibactin-producers. In perhaps the most direct evidence of colibactin’s carcinogenic potential, recent work has also shown that when mice are colonized with pks+ E. coli, colibactin directly alkylates DNA in gut epithelial cells, resulting in the formation of DNA adducts. Together, this evidence suggests that exposure to colibactin may increase risk for, or accelerate the development of, CRC via the mutagenic effects of DNA alkylation and crosslinking by colibactin. Despite this, no viable therapeutic strategy has emerged to prevent colibactin exposure, and no tools exist to study the effects of this pathway in the context of a complex, healthy gut-microbial community. This proposal aims to address these knowledge gaps by developing potent and specific small molecule inhibitors of colibactin biosynthesis. Such tool compounds will enable a more detailed study of how colibactin contributes to CRC progression and allow us to test the hypothesis that blocking colibactin production by pks+ bacteria using small molecules can lower the risk of developing CRC for the host. This research will both to explore a novel molecular target for therapeutic intervention in CRC development, as well as provide the wider scientific community with tools that will enable a more precise study of the impacts of small molecule toxins from commensal microbes on human health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule inhibitors for the study of colibactin-induced carcinogenesis by gut microbes
  • 批准号:
    9907706
  • 项目类别:
  • 资助金额:
    $4.55万
  • 财政年份:
    2020
  • 负责人:
    Matthew Robert Volpe
  • 依托单位:
海外基金